{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:06:52Z","timestamp":1792415212423,"version":"4.4.0"},"reference-count":64,"publisher":"Georg Thieme Verlag KG","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Experimental and clinical evidence obtained in the last 2 decades clearly indicates that protracted exposure to inappropriately elevated aldosterone levels causes significant changes in left ventricular structure and function. Animal studies have demonstrated that aldosterone induces myocardial inflammatory changes and fibrosis in the presence of a high salt diet. Moreover, the effects of aldosterone on the heart have been investigated in different clinical conditions. These conditions include systolic and diastolic heart failure, essential hypertension, and primary aldosteronism that offers a unique clinical model to study the cardiac effects of excess aldosterone because these effects are isolated from those of the renin-angiotensin axis. A relatively clear picture is emerging from these studies with regard to aldosterone-related changes in left ventricular mass and geometry. Conversely, no direct effect of aldosterone on left ventricular diastolic function can be demonstrated and improvement of diastolic function obtained in some studies that have employed mineralocorticoid receptor blockers could result from left ventricular mass reduction. Animal experiments demonstrate that effects of aldosterone on the left ventricle require high salt intake to occur, but the evidence of this contribution of salt to aldosterone-induced cardiac changes in humans remains weaker and needs further research. The article reviews the results of clinical studies addressing the role of aldosterone in regulation of LV remodeling and diastolic function, and focuses on the possible relevance of salt intake.<\/jats:p>","DOI":"10.1055\/s-0035-1565055","type":"journal-article","created":{"date-parts":[[2015,11,13]],"date-time":"2015-11-13T23:51:04Z","timestamp":1447458664000},"page":"981-986","source":"Crossref","is-referenced-by-count":39,"title":["Aldosterone and Left Ventricular Remodeling"],"prefix":"10.1055","volume":"47","author":[{"given":"G.","family":"Colussi","sequence":"first","affiliation":[{"name":"Hypertension Unit, Internal Medicine, Department of Experimental and Clinical Medical Science, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Brosolo","sequence":"first","affiliation":[{"name":"Hypertension Unit, Internal Medicine, Department of Experimental and Clinical Medical Science, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Novello","sequence":"first","affiliation":[{"name":"Hypertension Unit, Internal Medicine, Department of Experimental and Clinical Medical Science, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. A.","family":"Sechi","sequence":"first","affiliation":[{"name":"Hypertension Unit, Internal Medicine, Department of Experimental and Clinical Medical Science, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Catena","sequence":"additional","affiliation":[{"name":"Hypertension Unit, Internal Medicine, Department of Experimental and Clinical Medical Science, University of Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2015,11,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"B Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"B Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"F Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-0031-1291318","article-title":"Aldosterone and the heart: from basic research to clinical evidence","volume":"44","author":"C Catena","year":"2012","journal-title":"Horm Metab Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","article-title":"Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11-\u03b2-hydroxysteroid dehydrogenase in the human heart","volume":"92","author":"M Lombes","year":"1995","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/CS20070123","article-title":"Aldosterone and end-organ damage","volume":"113","author":"A M Marney","year":"2007","journal-title":"Clin Sci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2014.00168","article-title":"Aldosterone and the heart: still an unresolved issue?","volume":"5","author":"C Catena","year":"2014","journal-title":"Front Endocrinol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"R Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"ref9","first-page":"893","article-title":"Mineralcocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"C G Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/hyp.39.2.614","article-title":"Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading","volume":"39","author":"D V Martinez","year":"2002","journal-title":"Hypertension"},{"key":"ref11","first-page":"85","article-title":"Left ventricular hypertrophy: an independent risk factor","volume":"20","author":"E D Frohlich","year":"1990","journal-title":"Cardiovasc Clin"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/CIRCULATIONAHA.108.845792","article-title":"The progression of hypertensive heart disease","volume":"123","author":"M H Drazner","year":"2011","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/eurheartj\/ehr292","article-title":"Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction","volume":"33","author":"F Edelman","year":"2012","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/CIRCULATIONAHA.108.817411","article-title":"Relations of biomarkers representing distinct biological pathways to left ventricular geometry","volume":"118","author":"R S Velagaleti","year":"2008","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jpeds.2009.02.029","article-title":"Blood-aldosterone-to-renin ratio, ambulatory blood pressure, and left ventricular mass in children","volume":"155","author":"R Li","year":"2009","journal-title":"J Pediatr"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1210\/jc.2005-0681","article-title":"Evidence of abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I","volume":"90","author":"M Stowasser","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/ajh\/6.11.907","article-title":"Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma","volume":"6","author":"T Denolle","year":"1993","journal-title":"Am J Hypertens"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","article-title":"Changes in left ventricular anatomy and function in hypertension and primary aldosteronism","volume":"27","author":"G P Rossi","year":"1996","journal-title":"Hypertension"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.CIR.95.6.1471","article-title":"Remodeling of the left ventricle in primary aldosteronism due to Conn\u2019s adenoma","volume":"95","author":"G P Rossi","year":"1997","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1161\/01.HYP.29.3.723","article-title":"Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism","volume":"29","author":"Y Shigematsu","year":"1997","journal-title":"Hypertension"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1291\/hypres.20.85","article-title":"Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension","volume":"20","author":"A Tanabe","year":"1997","journal-title":"Hypertens Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","article-title":"Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism","volume":"50","author":"C Catena","year":"2007","journal-title":"Hypertension"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"294594","DOI":"10.1155\/2013\/294594","article-title":"Twenty-four-hour urinary aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism","author":"C S Hung","year":"2013","journal-title":"Sci World J"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/HYPERTENSIONAHA.108.114140","article-title":"Inappropriate left ventricular mass in patients with primary aldosteronism","volume":"52","author":"M L Muiesan","year":"2008","journal-title":"Hypertension"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/01.HYP.0000023182.68420.EB","article-title":"Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism","volume":"40","author":"G P Rossi","year":"2002","journal-title":"Hypertension"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1055\/s-0032-1301902","article-title":"Predictive factors of left ventricular mass changes after treatment of primary aldosteronism","volume":"44","author":"C Catena","year":"2012","journal-title":"Horm Metab Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","article-title":"Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism","volume":"62","author":"G P Rossi","year":"2013","journal-title":"Hypertension"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/HJH.0b013e3280108e6f","article-title":"Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study","volume":"25","author":"G Giacchetti","year":"2007","journal-title":"J Hypertens"},{"key":"ref29","first-page":"274","article-title":"Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment","volume":"35","author":"G Bernini","year":"2012","journal-title":"J Endocr Invest"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/ajh\/hpu154","article-title":"Adrenalectomy is comparable to medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies","volume":"28","author":"L Marzano","year":"2015","journal-title":"Am J Hypertens"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1161\/HYPERTENSIONAHA.110.156273","article-title":"Hyperaldosteronism and left ventricular hypertrophy","volume":"56","author":"L A Sechi","year":"2010","journal-title":"Hypertension"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1253\/circj.71.716","article-title":"Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide","volume":"71","author":"T Nakahara","year":"2007","journal-title":"Circ J"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.amjhyper.2005.06.035","article-title":"Aldosterone and left ventricular hypertrophy in Afro-Caribbean subjects with low renin hypertension","volume":"19","author":"A D Stewart","year":"2006","journal-title":"Am J Hypertens"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ajh.2008.225","article-title":"Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome","volume":"21","author":"G Mul\u00e8","year":"2008","journal-title":"Am J Hypertens"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ajh\/hps006","article-title":"Association of aldosterone with left ventricular mass in hypertension: interaction with plasma fibrinogen levels","volume":"26","author":"C Catena","year":"2013","journal-title":"Am J Hypertens"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1291\/hypres.25.49","article-title":"Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension","volume":"25","author":"Y Iwashima","year":"2002","journal-title":"Hypertens Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1291\/hypres.25.837","article-title":"Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension","volume":"25","author":"A Sato","year":"2002","journal-title":"Hypertension Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1253\/circj.70.995","article-title":"Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy","volume":"70","author":"I Taniguchi","year":"2006","journal-title":"Circ J"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalalpril, and eplerenone\/enelapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"B Pitt","year":"2003","journal-title":"Circulation"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/HYPERTENSIONAHA.109.141531","article-title":"Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective study","volume":"55","author":"K Gaddam","year":"2010","journal-title":"Hypertension"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"R Rocha","year":"2002","journal-title":"Am J Physiol (Heart Circ Physiol)"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/HYPERTENSIONAHA.107.098012","article-title":"Mineralocorticoid receptor activation and oxidative stress","volume":"50","author":"J W Funder","year":"2007","journal-title":"Hypertension"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/1440-1681.12145","article-title":"Aldosterone, organ damage and dietary salt","volume":"40","author":"C Catena","year":"2013","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00424-014-1658-0","article-title":"Primary aldosteronism and salt","volume":"467","author":"J W Funder","year":"2015","journal-title":"Plugers Arch"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0002-9149(00)00728-1","article-title":"Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects","volume":"85","author":"M P Schlaich","year":"2000","journal-title":"Am J Cardiol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/HYPERTENSIONAHA.109.130492","article-title":"Independent relations of left ventricular structure with the 24-hour urinary excretion of sodium and aldosterone","volume":"54","author":"Y Jin","year":"2009","journal-title":"Hypertension"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/HYPERTENSIONAHA.110.159277","article-title":"Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system","volume":"56","author":"G du Cailar","year":"2010","journal-title":"Hypertension"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1210\/jc.2011-0354","article-title":"Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: Results of a case-control study","volume":"26","author":"E Pimenta","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline","volume":"93","author":"J W Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref51","first-page":"50","article-title":"Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new","volume":"2","author":"C Catena","year":"2012","journal-title":"Am J Cardiovasc Dis"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"H1484","DOI":"10.1152\/ajpheart.01000.2010","article-title":"Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression","volume":"300","author":"J Habibi","year":"2002","journal-title":"Am J Physiol (Heart Circ Physiol)"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.304","article-title":"Heart failure with preserved ejection fraction: uncertainties and dilemmas","volume":"17","author":"R Ferrari","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2009.08.021","article-title":"Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone","volume":"54","author":"G J Mak","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.amjcard.2010.07.018","article-title":"Effect of spironolactone on left ventricular systolic and diastolic in patients with early stage chronic kidney disease","volume":"106","author":"N C Edwards","year":"2010","journal-title":"Am J Cardiol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosteronism antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure","volume":"110","author":"P M Mottram","year":"2004","journal-title":"Circulation"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"F Edelmann","year":"2013","journal-title":"JAMA"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"B Pitt","year":"2014","journal-title":"NEJM"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"M A Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCIMAGING.112.974576","article-title":"Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study","volume":"5","author":"E M Freel","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinbiochem.2014.05.062","article-title":"Association between urine aldosterone and diastolic function in patients with primary aldosteronism and essential hypertension","volume":"47","author":"Y Y Chang","year":"2014","journal-title":"Clin Biochem"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/01.HYP.0000036399.80194.D8","article-title":"Aldosterone antagonist improves diastolic function in essential hypertension","volume":"40","author":"A M Grandi","year":"2002","journal-title":"Hypertension"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/jhh.2014.83","article-title":"Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy","volume":"29","author":"A Gupta","year":"2015","journal-title":"J Hum Hypertens"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/HYPERTENSIONAHA.115.05285","article-title":"Plasma aldosterone and left ventricular diastolic function in treatment-na\u00efve patients with hypertension: a Tissue-Doppler Imaging Study","volume":"65","author":"C Catena","year":"2015","journal-title":"Hypertension"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1540-8175.2006.00215.x","article-title":"Technical aspects of diastology: why mitral inflow and tissue Doppler imaging are the preferred parameters?","volume":"23","author":"R L Bess","year":"2006","journal-title":"Echocardiography"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0035-1565055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T11:49:34Z","timestamp":1748692174000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0035-1565055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,13]]},"references-count":64,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2015,12,14]]},"published-print":{"date-parts":[[2015,12]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0035-1565055","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,13]]}}}